Granules India’s Bonthapally Facility Completed US FDA Inspection

August 14, 2019 Gubba Pharma In E News

Granules India Ltd’s Bonthapally facility located at Hyderabad, Telangana, India has completed the US FDA inspection from 22nd July 2019 to 26th July 2019 with one(1) 483 observation which is procedural in nature. The Company will respond to this observation within the stipulated time period.
Bonthapally facility is one of the world’s largest single site Paracetamol API manufacturing plant by volume. Along with Paracetamol APIs, the Company has established Metformin and Guaifenesin API manufacturing plants in the same facility. The Company has already received approval from US FDA for Metformin API from this facility.
Shares of GRANULES INDIA LTD. was last trading in BSE at Rs.85.25 as compared to the previous close of Rs. 85.05. The total number of shares traded during the day was 17496 in over 369 trades.
The stock hit an intraday high of Rs. 86 and intraday low of 84.25. The net turnover during the day was Rs. 1489074.

Source : equitybulls

Gubba Group

About the author

Gubba Group: